Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:NVTS NASDAQ:VIGL NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.57+0.9%$5.07$3.21▼$7.18$1.57B0.743.40 million shs4.16 million shsNVTSNavitas Semiconductor$5.54-3.3%$6.77$1.52▼$9.48$1.22B313.26 million shs10.54 million shsVIGLVigil Neuroscience$8.05$8.04$1.31▼$8.10$383.91M3.331.09 million shsN/AWVEWAVE Life Sciences$8.18+2.3%$8.40$5.04▼$16.74$1.27B-1.151.99 million shs3.44 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.92%+2.98%+28.07%+78.53%+15.87%NVTSNavitas Semiconductor-3.32%-8.28%-18.17%-10.36%+119.84%VIGLVigil Neuroscience0.00%0.00%-0.25%+2.16%+136.76%WVEWAVE Life Sciences+2.25%-17.62%-7.47%+13.30%+59.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.57+0.9%$5.07$3.21▼$7.18$1.57B0.743.40 million shs4.16 million shsNVTSNavitas Semiconductor$5.54-3.3%$6.77$1.52▼$9.48$1.22B313.26 million shs10.54 million shsVIGLVigil Neuroscience$8.05$8.04$1.31▼$8.10$383.91M3.331.09 million shsN/AWVEWAVE Life Sciences$8.18+2.3%$8.40$5.04▼$16.74$1.27B-1.151.99 million shs3.44 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.92%+2.98%+28.07%+78.53%+15.87%NVTSNavitas Semiconductor-3.32%-8.28%-18.17%-10.36%+119.84%VIGLVigil Neuroscience0.00%0.00%-0.25%+2.16%+136.76%WVEWAVE Life Sciences+2.25%-17.62%-7.47%+13.30%+59.77%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.75N/AN/A$0.73 per share9.00NVTSNavitas Semiconductor$83.30M14.17N/AN/A$1.85 per share2.99VIGLVigil NeuroscienceN/AN/AN/AN/A$1.75 per shareN/AWVEWAVE Life Sciences$108.30M12.02N/AN/A$1.37 per share5.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A21.19N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)NVTSNavitas Semiconductor-$84.60M-$0.65N/AN/AN/A-182.63%-18.16%-16.26%11/3/2025 (Estimated)VIGLVigil Neuroscience-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%11/6/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest VIGL, NVTS, ARDX, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million8/4/2025Q2 2025NVTSNavitas Semiconductor-$0.05-$0.05N/A-$0.25$14.43 million$14.49 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ANVTSNavitas SemiconductorN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03NVTSNavitas SemiconductorN/A8.237.59VIGLVigil NeuroscienceN/A2.972.97WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%NVTSNavitas Semiconductor46.14%VIGLVigil Neuroscience83.64%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%NVTSNavitas Semiconductor29.90%VIGLVigil Neuroscience18.01%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableNVTSNavitas Semiconductor160213.11 million149.39 millionOptionableVIGLVigil Neuroscience4047.69 million39.10 millionNot OptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableVIGL, NVTS, ARDX, and WVE HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Earns Buy Rating from HC Wainwright1 hour ago | americanbankingnews.comWave Crashes Despite Successful RNA Editing in AATD StudySeptember 4 at 4:45 PM | biospace.comB683 Capital Management LLC Purchases 140,000 Shares of WAVE Life Sciences Ltd. $WVESeptember 4 at 7:42 AM | marketbeat.comJump Financial LLC Trims Stake in WAVE Life Sciences Ltd. $WVESeptember 4 at 3:56 AM | marketbeat.comWave RNA editing restores enzyme in genetic condition but underwhelms investorsSeptember 4 at 2:40 AM | fiercebiotech.comFWave shares sink on new study results for RNA editing drugSeptember 4 at 2:40 AM | finance.yahoo.comForecasting The Future: 7 Analyst Projections For WAVE Life SciencesSeptember 4 at 2:40 AM | benzinga.comWave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out WhySeptember 4 at 2:40 AM | msn.comWave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference TranscriptSeptember 3 at 4:06 PM | seekingalpha.comWave Life Sciences Ltd. (WVE) Special Call - SlideshowSeptember 3 at 11:02 AM | seekingalpha.comWave Life Sciences stock tumbles after WVE-006 trial updateSeptember 3 at 8:11 AM | in.investing.comWave Life Sciences stock tumbles after WVE-006 trial updateSeptember 3 at 8:11 AM | in.investing.comWave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin DeficiencySeptember 3 at 7:30 AM | globenewswire.comDriehaus Capital Management LLC Sells 353,850 Shares of WAVE Life Sciences Ltd. $WVEAugust 31, 2025 | marketbeat.comSiren L.L.C. Cuts Stock Holdings in WAVE Life Sciences Ltd. $WVEAugust 31, 2025 | marketbeat.comWave Life Sciences Ltd. (WVE) Gains Momentum With Multiple RNA WinsAugust 29, 2025 | finance.yahoo.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Charles Schwab Investment Management Inc.August 29, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Acquired by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Raised by Martingale Asset Management L PAugust 28, 2025 | marketbeat.comGregory Verdine Sells 10,000 Shares of WAVE Life Sciences (NASDAQ:WVE) StockAugust 27, 2025 | insidertrades.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4By Leo Miller | August 18, 2025Navitas Stock's Dip: A Calculated Risk or a Clear Buy Signal?By Jeffrey Neal Johnson | August 7, 2025VIGL, NVTS, ARDX, and WVE Company DescriptionsArdelyx NASDAQ:ARDX$6.57 +0.06 (+0.92%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$6.56 -0.01 (-0.15%) As of 09/4/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Navitas Semiconductor NASDAQ:NVTS$5.54 -0.19 (-3.32%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$5.56 +0.02 (+0.36%) As of 09/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Navitas Semiconductor Corporation designs, develops, and markets gallium nitride power integrated circuits, silicon carbide, associated high-speed silicon system controllers, and digital isolators used in power conversion and charging. The company's products are used in mobile, consumer, data center, solar, electric vehicle, industrial motor drive, smart grid, and transportation applications. It operates in the United States, Europe, China, rest of Asia, and internationally. The company was founded in 2013 and is based in Torrance, California.Vigil Neuroscience NASDAQ:VIGL$8.05 0.00 (0.00%) As of 08/5/2025Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.WAVE Life Sciences NASDAQ:WVE$8.18 +0.18 (+2.25%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$8.07 -0.11 (-1.34%) As of 09/4/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
